 Home > Active Ingredient News > Drugs Articles > Lilly to develop next-generation ADC therapeutics in $1.7 billion R&D partnership

Lilly to develop next-generation ADC therapeutics in $1.7 billion R&D partnership

 Last Update: 2022-03-06
 Source: Internet
 Author: User

Tags

standing platform

target sell drug tests

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ImmunoGen announced today that it has entered into a global research and development collaboration with Eli Lilly and Company
.

Grant Eli Lilly exclusive rights to develop and commercialize antibody drug conjugates (ADCs) against Eli Lilly's selected targets using ImmunoGen's innovative camptothecin technology platform

Camptothecin is an important anticancer drug targeting type I topoisomerase
.

ImmunoGen's proprietary camptothecin and linker design is designed to optimize existing camptothecin technology, potentially offering a wider therapeutic window and enhancing safety and efficacy

Under the agreement, Eli Lilly will pay ImmunoGen an upfront payment of $13 million and select initial targets
.

Lilly has the right to choose more targets

References:

[1] ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.

[1] ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.
7 Billion.
Retrieved February 15, 2022, from https://investor.
immunogen.
com/news-releases/news- release-details/immunogen-announces-global-multi-target-license-agreement-its

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.